Article
ClonoScreen3D: a novel three-dimensional clonogenic screening platform for identification of radiosensitizers for glioblastoma
2023-10-04
Abstract excerpt
<h4>Purpose</h4> Glioblastoma (GBM) is a lethal brain tumour. Standard of care treatment comprising surgery, radiation and chemotherapy results in median survival rates of 12-15 months. Molecular targeted agents identified using conventional two-dimensional (2D) in vitro models of GBM have failed to improve outcome in patients, rendering such models inadequate for therapeutic target identification. We developed...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 4d57e4d0-9d6e-537f-97e7-dea76e3791f9
- DOI
- 10.1101/2023.10.04.560635
